Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Nilotinib (L01ea03), Without Administration Dispersed in Applesauce (Pureed Apple...

Open House Discount Contracts 2024-14

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Perindopril and Indapamide (Exclusively Perindopril as Arginine Salt), Atc C09ba54 F. D. Z. 01.02.25 - 31.01.27

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Baricitinib, (Obo) Atc L04aa37 for the Period February 1St, 2025 - January 31St, 2027

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Peg-Epoetin Beta, (Obo) Atc B03xa03 for the Period February 1St, 2025 - January 31St, 2027

Open House Drug Discount Agreements Buserelin, Atc L02ae01

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Flupentixol, (Obg) Atc N05af01 for the Period February 1St, 2025 - January 31St, 2027

Open House Drug Discount Agreements Tapentadol in the Non-Sustained-Release Dosage Forms, Atc N02ax06

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Mepolizumab, (Obo) Atc R03dx09 for the Period February 1St, 2025 - January 31St, 2027

Open House Drug Discount Agreements Trientin, Atc A16ax12